Counterpoint Mutual Funds LLC Buys Shares of 24,787 Enovis Corporation $ENOV

Counterpoint Mutual Funds LLC bought a new position in Enovis Corporation (NYSE:ENOV) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 24,787 shares of the company’s stock, valued at approximately $564,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Rubric Capital Management LP acquired a new position in shares of Enovis in the 3rd quarter valued at $83,435,000. AQR Capital Management LLC increased its position in shares of Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock valued at $15,627,000 after buying an additional 434,646 shares in the last quarter. Paradigm Capital Management Inc. NY raised its stake in Enovis by 41.6% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 1,113,300 shares of the company’s stock worth $34,913,000 after buying an additional 326,900 shares during the period. ExodusPoint Capital Management LP raised its stake in Enovis by 163.4% during the 4th quarter. ExodusPoint Capital Management LP now owns 508,971 shares of the company’s stock worth $13,559,000 after buying an additional 315,711 shares during the period. Finally, Soleus Capital Management L.P. bought a new position in Enovis during the second quarter worth about $9,878,000. 98.45% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert purchased 1,200 shares of the stock in a transaction on Thursday, June 11th. The shares were purchased at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the purchase, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have acquired a total of 4,200 shares of company stock valued at $92,084 over the last ninety days. 2.90% of the stock is currently owned by company insiders.

Enovis Trading Up 0.4%

NYSE:ENOV opened at $22.60 on Friday. The company has a market cap of $1.30 billion, a P/E ratio of -1.14 and a beta of 1.39. Enovis Corporation has a twelve month low of $19.14 and a twelve month high of $36.82. The business has a 50 day moving average price of $23.23 and a two-hundred day moving average price of $23.86. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The company had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company earned $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts expect that Enovis Corporation will post 3.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ENOV. Zacks Research cut Enovis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, June 30th. BTIG Research reaffirmed a “buy” rating and set a $39.00 price target on shares of Enovis in a research report on Friday, May 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. William Blair initiated coverage on Enovis in a research report on Friday, April 17th. They issued an “outperform” rating for the company. Finally, Wells Fargo & Company decreased their price objective on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and a consensus price target of $44.50.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.